Macrophage Therapeutics, A Subsidiary Of Navidea Biopharmaceuticals, Appoints Leading Experts To Therapeutics-Focused Scientific Advisory Board

Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced the appointment of leading experts to a newly formed scientific advisory board (SAB) to serve as a strategic resource to Macrophage Therapeutics as it looks to develop therapeutic applications for Navidea’s innovative Manocept™ platform. The inaugural SAB consortium is comprised of world-renowned scientists and clinicians in the areas of oncology, immunology, autoimmune diseases and macrophage biology.

Help employers find you! Check out all the jobs and post your resume.